- Home
- SAGE
as 11-20-2024 4:00pm EST
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 462.2M | IPO Year: | 2014 |
| Target Price: | $12.89 | AVG Volume (30 days): | 854.9K |
| Analyst Decision: | Hold | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.62 - $28.26 | Next Earning Date: | 10-29-2024 |
| Revenue: | $106,399,000 | Revenue Growth: | 837.60% |
| Revenue Growth (this year): | -49.99% | Revenue Growth (next year): | 118.26% |
Latest Sage Therapeutics Inc. News
SAGE Breaking Stock News: Dive into SAGE Ticker-Specific Updates for Smart Investing
Benzinga
21 hours ago
After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
MT Newswires
a day ago
Wedbush Cuts Price Target on SAGE Therapeutics to $4 From $7, Maintains Neutral Rating
MT Newswires
a day ago
SAGE Therapeutics' Study of Dalzanemdor Fails to Meet Primary, Secondary Endpoints
BioPharma Dive
a day ago
Sage’s string of research failures continues
Business Wire
a day ago
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
TipRanks
21 days ago
Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler
Zacks
22 days ago
SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
BioPharma Dive
22 days ago
Biogen, Sage admit a defeat in major depression
Compare SAGE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SAGE Sage Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.